Cas:116834-64-1 4-(quinolin-8-ylsulfonylamino)benzoic acid manufacturer & supplier

Chemical Name:4-(quinolin-8-ylsulfonylamino)benzoic acid

CAS.NO:116834-64-1

Synonyms:4-(quinolin-8-ylsulfonylamino)benzoic acid

Molecular Formula:C₁₆H₁₂N₂O₄S

Molecular Weight:328.34200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:104.74000

Exact Mass:328.05200

LogP:3.88760

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-(quinolin-8-ylsulfonylamino)benzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(quinolin-8-ylsulfonylamino)benzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(quinolin-8-ylsulfonylamino)benzoic acid Use and application,4-(quinolin-8-ylsulfonylamino)benzoic acid technical grade,usp/ep/jp grade.

Related News: Since the listing of high-barrier generic drugs involves quickly bypassing or challenging process patents of original research products within a short period of time, API companies play an important role in the process of marketing and sales of generic drugs. 4-(quinolin-8-ylsulfonylamino)benzoic acid manufacturer Patients given the vaccine also experienced a reduction in cerebrospinal fluid biomarkers of abnormal tau, results show. 4-(quinolin-8-ylsulfonylamino)benzoic acid supplier In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of ��predictable�� clinical value for life-threatening diseases for which effective treatment is not immediately available. 4-(quinolin-8-ylsulfonylamino)benzoic acid vendor In an August overhaul to its drug administration law, Beijing said conditional approval could be granted to some still-under-research medicines of ��predictable�� clinical value for life-threatening diseases for which effective treatment is not immediately available. 4-(quinolin-8-ylsulfonylamino)benzoic acid factory The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.